Piezo-surgery Versus Conventional Drills

This was a pilot, parallel-group, doble-blinded, split-mouth, randomized clinical trial.

The study included six patients with bilateral partial edentulism, having in total 12 maxillary or mandibular edentulous alveolar ridges. All patients had been referred to the Unit of Oral and Maxillofacial Surgery, Alma Mater Studiorum, University of Bologna, Italy.

The alveolar ridges were randomized into two groups using a computer-generated method: Group A included six regions where implant sites were prepared by piezosurgery, and Group B six regions prepared by conventional drilling.

Surgical and prosthetic protocol In Group A, all implant sites were prepared with a piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy). One or two implants were placed in each edentulous ridge along with an additional 3.3 x 8.5 mm implant, termed a "study fixture", in an adjacent area. In Group B, all implant sites were prepared with conventional drills according to the manufacturer's protocol (Premium, Sweden & Martina, Due Carrare, Padova, Italy); similarly to group A, one or two implants were placed in each edentulous ridge, and an additional 3.3 x 8.5 mm "study-fixture" was placed in the adjacent area.

After cover screw placement, a parallel periapical radiograph was taken and the flap was sutured with 4-0 Vicryl. After surgery, antibiotic therapy (1 g amoxicillin and clavulanic acid every 8 h for 4 days), analgesic therapy (nimesulid 200 mg/day for 2 days, continued if pain persisted), and antiseptic therapy (chlorhexidine 0.2% [w/v] three times daily), were prescribed.

• Clinical procedure II - Re-entry Surgery At 28 days after surgery (T1), all "study-fixtures" in both groups were explanted using a trephine drill, taking care to explant the fixture with 0.5 mm of circumferential peri-implant bone tissue. The timing of re-entry surgery (T1) was fixed to be 28 days based on a previous animal study 12. All retrieved implants with bone tissue biopsies were fixed in 4% (v/v) formalin prior to histological analysis (Figure 7,8).
• Clinical procedure III - Prosthetic restoration At 3 months after surgery (T2), a mid-crestal horizontal incisions of keratinized tissue, without vertical incisions, was performed to expose the submerged implants and place healing screws. One month later (T3), implant-supported, metal-ceramic fixed restorations were delivered to the patients to allow functional loading.
• Data collection During surgery and at all postoperative visits (T0, T1, T2, and T3), clinical and radiographic data were recorded by a single operator (E.V.). Histological, histomorphometric, and immunohistochemical data were recorded on the same forms after bone biopsy and laboratory analyses (T1).
• Laboratory data

All specimens were fully analyzed in terms of the percentages of necrotic bone area (NBA%) and newly-formed bone area (nFBA%), and the ratios of these values to total bone area (TBA). For each specimen, the authors identified three different areas proceeding from the surface of the fixture toward the border of the biopsy: zone 1, necrotic bone undergoing remodeling; zone 2, woven and newly formed bone; and zone 3, native bone. For each zone, we recorded:

• Absolute and relative areas: Zone areas were expressed as absolute values (mm2) and relative values (%) with respect to the total areas.
• Inflammatory infiltrates: The presence and type of inflammatory infiltrate (if present) was classified; we scored inflammation as absent (no inflammatory cells), minimal (< 5 cells/mm2), or present (> 5 cells/mm2).
• CD31 (a vascular endothelium differentiation and neo-osteogenesis marker): CD31 expression was recorded as the number of positive vessels/mm2
• SATB2 (a osteoblastic cell differentiation and osteogenesis marker): SATB2 expression was recorded as the number of positive spots/mm2.

Criteria: Inclusion Criteria:

• bilateral edentulous sites in mandibles or maxillae that did not require bone regeneration prior to implant placement;
• American Society of Anesthesiologists (ASA) status 1;
• the capacity to understand and accept the conditions of the study;
• continuing participation for at least 1 year of follow-up.

Exclusion criteria

• Previous bone augmentation of the sites to be treated;
• poor oral hygiene;
• smoking > 10 cigarettes/day;
• abuse of alcohol or drugs;
• pregnancy;
• acute local or systemic infection;
• uncontrolled diabetes or other metabolic disease;
• severe hepatic or renal dysfunction;
• HIV, HBV, or HCV infection;
• chemotherapy or radiotherapy within the past 5 years;
• current immunosuppressive therapy;
• an autoimmune disorder;
• bisphosphonate therapy